Figure 3.
Figure 3. Assessment of the self-renewal potential of engrafting AML cells by serial transplantation of 3 AML samples. (A) Setup of secondary transplantation experiments. huCD45+ cells harvested from a scaffold or from the BM of primary huBM-sc mice were injected into the scaffolds of secondary recipient NSG mice implanted with the humanized niches 6 to 8 weeks before the transplantation of leukemic cells. (B,D,F) Representative FACS analysis of secondary recipient mice of AML #2, AML #3, and AML #1, respectively. (C,E,G) In vivo tumor growth rates of the biggest tumor scaffold in secondary transplanted mice from AML #2, AML #3, and AML #1, respectively. Each colored line represents 1 mouse, and the cell dosage and source are depicted in the corresponding legend. Tumor size (cm3) was used as the end point of the experimental period. SC, human scaffold.

Assessment of the self-renewal potential of engrafting AML cells by serial transplantation of 3 AML samples. (A) Setup of secondary transplantation experiments. huCD45+ cells harvested from a scaffold or from the BM of primary huBM-sc mice were injected into the scaffolds of secondary recipient NSG mice implanted with the humanized niches 6 to 8 weeks before the transplantation of leukemic cells. (B,D,F) Representative FACS analysis of secondary recipient mice of AML #2, AML #3, and AML #1, respectively. (C,E,G) In vivo tumor growth rates of the biggest tumor scaffold in secondary transplanted mice from AML #2, AML #3, and AML #1, respectively. Each colored line represents 1 mouse, and the cell dosage and source are depicted in the corresponding legend. Tumor size (cm3) was used as the end point of the experimental period. SC, human scaffold.

Close Modal

or Create an Account

Close Modal
Close Modal